Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of child bearing age (15 to 49 years). This disease is characterized by the formation of cysts on the ovaries leading to an insufficiency of the ovulation initiating hormone in the female body. The global market for PCOS drugs is on an upward swing given the increasing number of cases of patients inflicted with the disease. The global polycystic ovary syndrome drugs market revenue is estimated to reach US$ 1,154.8 Mn by 2024, expanding at a CAGR of 4.6% during the forecast period (2016–2024).
Find Out More about the Report Coverage
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Addex Therapeutics Ltd.
- Merck KGaA
- AstraZeneca plc.
- Bristol Myers Squibb Co.
- Ferring Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc.
Key market dynamics
Growth of the global PCOS drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. PCOS often leads to hirsutism, obesity, and infertility and hence the need for effective management of associated diseases is likely to boost the demand for PCOS drugs.
Also, a growing popularity of combination drugs and their rising adoption among the patient population is expected to boost revenue growth of the PCOS drugs market in the coming years. However, lack of FDA approved drugs and increasing side effects associated with generics might hamper market growth during the forecast period.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Market forecast by segmentation
The global PCOS drugs market is segmented based on Drug Class (Oral Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors, Diuretics) and Distribution Channel (Hospital Pharmacies, Drug Stores/OTC, E-Commerce, Fertility Clinics).
The contraceptive drug class segment is expected to witness 1.6X increase in revenue by the end of 2024 and is projected to register a CAGR of 5.4% over the forecast period – reaching a market value of US$ 355.7 Mn by the end of 2024. The insulin sensitizing agent segment is estimated to register a CAGR of 4.8% during the forecast period. The Anti-Depressants drug class segment is estimated to be valued at US$ 51.1 Mn by the end of 2016, registering a CAGR of 3.0%.
Among distribution channels, the hospital pharmacies segment is estimated to account for 48.3% market share by 2016, which is anticipated to increase to 49.8% by 2024. This segment is expected to continue to lead the market in terms of revenue growth. The E-commerce segment is estimated to be valued at US$ 118.8 Mn by 2016 and is expected to expand at a CAGR of 4.3%.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The global PCOS drugs market has been segmented into five major regions namely North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. In terms of value, North America and Europe are estimated to dominate the market, collectively accounting for ~57% share of the overall market by the end of 2016. Latin America and Asia Pacific are estimated to be the fastest growing emerging markets. Revenue from the APAC market is expected to expand at a robust CAGR of 5.5% during the forecast period.
Explore Persistence Market Research’s expertise in promulgation of the business !
PCOS drugs market leaders
Some of the key players operating in the global PCOS drugs drug market include Sanofi, Novartis, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and AstraZeneca Plc. As there are no FDA approved drugs available in the market for the treatment of PCOS, leading companies are investing in R&D activities to develop a novel drug for treating PCOS. Moreover, companies are focusing on creating awareness related to feminine hygiene through CSR initiatives in developing regions such as APAC and MEA.
Currently, there are no specific diagnostic tests available for the detection of PCOS; however, blood tests, physical examination, vaginal ultrasound, and medical history analysis are widely recommended by general physicians and gynecologists. While there is no cure for PCOS, its symptoms and associated conditions can be managed with the help of lifestyle modification activities, weight loss management, and medications. Currently, no drugs are approved by the FDA and EMA for PCOS. However, oral contraceptives, insulin sensitizing agents, and aromatase inhibitors are used as first line agents for the treatment of irregular menstruation, diabetes, and facial hair growth respectively.